Acta Neurologica Scandinavica. Supplementum This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Advances in genetic diagnosis of neurological disorders.
Abstract Neurogenetics has developed enormously in recent years, and the genetic basis of human disorders is being unravelled rapidly. Many neurological disorders are Mendelian disorders, caused by mutations in genes involved in normal function of the brain, spinal cord, peripheral nerves or muscles. Due to high costs and time-consuming procedures, genetic tests have normally been performed late in the diagnostic process, when clinical examination and other tests have indicated a specific gene as the likely disease cause. Many neurological phenotypes are genetically very heterogeneous, and testing of all p...
Source: Acta Neurologica Scandinavica. Supplementum - March 9, 2014 Category: Neurology Authors: Toft M Tags: Acta Neurol Scand Suppl Source Type: research

Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries.
CONCLUSIONS: This study confirms an optimal and unbiased case finding in both databases. Our calculated prevalence and incidence rates are in line with previous population-based studies. There was good agreement in prevalence reported from the two databases. The discrepancy in incidence is expected to diminish as years of study are increasing in NorPD. PMID: 24588503 [PubMed - in process] (Source: Acta Neurologica Scandinavica. Supplementum)
Source: Acta Neurologica Scandinavica. Supplementum - March 9, 2014 Category: Neurology Authors: Andersen JB, Heldal AT, Engeland A, Gilhus NE Tags: Acta Neurol Scand Suppl Source Type: research

MRI evaluation of grey matter atrophy and disease course in multiple sclerosis: an overview of current knowledge.
Abstract Multiple sclerosis (MS) is characterized by chronic inflammation of the central nervous system, and magnetic resonance imaging (MRI) is used as both a diagnostic tool and a parameter in the clinical evaluation. Multiple sclerosis was long regarded as a disease of the white matter (WM) in the brain, which can be visualized by the standard MRI used in daily practice. There is an increasing amount of evidence that grey matter (GM) pathology plays a role from the start of the MS disease and throughout the clinical course. Grey matter atrophy, both cortical and central, is present in the early course o...
Source: Acta Neurologica Scandinavica. Supplementum - March 9, 2014 Category: Neurology Authors: Jacobsen CO, Farbu E Tags: Acta Neurol Scand Suppl Source Type: research

Mild stroke: safety and outcome in patients receiving thrombolysis.
CONCLUSIONS: This study highlights the efficacy of rt-PA in patients with acute cerebral ischemia presenting with mild symptoms and confirms the low-risk profile of this treatment. PMID: 24588505 [PubMed - in process] (Source: Acta Neurologica Scandinavica. Supplementum)
Source: Acta Neurologica Scandinavica. Supplementum - March 9, 2014 Category: Neurology Authors: Logallo N, Kvistad CE, Naess H, Waje-Andreassen U, Thomassen L Tags: Acta Neurol Scand Suppl Source Type: research

Diffusion-weighted lesions in acute ischaemic stroke patients with migraine.
CONCLUSIONS: Migraine was associated with small cortical infarctions. This association may be due to cortical spreading depression. PMID: 24588506 [PubMed - in process] (Source: Acta Neurologica Scandinavica. Supplementum)
Source: Acta Neurologica Scandinavica. Supplementum - March 9, 2014 Category: Neurology Authors: Oygarden H, Kvistad CE, Bjørk M, Thomassen L, Waje-Andreassen U, Naess H Tags: Acta Neurol Scand Suppl Source Type: research

Sleep quality and arousal in migraine and tension-type headache: the headache-sleep study.
CONCLUSIONS: We hypothesize that TTH and NSM patients on the average need more sleep than healthy controls. SM patients seem more susceptible to sleep disturbances. Inadequate rest might be an attack-precipitating- and hyperalgesia-inducing factor. PMID: 24588507 [PubMed - in process] (Source: Acta Neurologica Scandinavica. Supplementum)
Source: Acta Neurologica Scandinavica. Supplementum - March 9, 2014 Category: Neurology Authors: Engstrøm M, Hagen K, Bjørk MH, Stovner LJ, Sand T Tags: Acta Neurol Scand Suppl Source Type: research

This supplement provides an overview of the development of perampanel, the first non-competitive AMPA-type glutamate receptor antagonist to be developed as an adjunctive treatment for refractory partial-onset seizures. Introduction.
PMID: 23480149 [PubMed - in process] (Source: Acta Neurologica Scandinavica. Supplementum)
Source: Acta Neurologica Scandinavica. Supplementum - May 25, 2013 Category: Neurology Authors: Ben-Menachem E Tags: Acta Neurol Scand Suppl Source Type: research

Development of perampanel in epilepsy.
Abstract Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors play a key role in mediating glutamatergic transmission in the cortex. Perampanel (2-[2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl] benzonitrile) is a potent, orally active, highly selective, non-competitive AMPA-type glutamate receptor antagonist, identified via a focused discovery program at Eisai Research Laboratories. Development of perampanel as adjunctive therapy for the treatment of partial-onset seizures was planned in keeping with regulatory guidance and guidelines on antiepileptic drug (AED)...
Source: Acta Neurologica Scandinavica. Supplementum - May 25, 2013 Category: Neurology Authors: Satlin A, Kramer LD, Laurenza A Tags: Acta Neurol Scand Suppl Source Type: research

AMPA receptors as a molecular target in epilepsy therapy.
Abstract Epileptic seizures occur as a result of episodic abnormal synchronous discharges in cerebral neuronal networks. Although a variety of non-conventional mechanisms may play a role in epileptic synchronization, cascading excitation within networks of synaptically connected excitatory glutamatergic neurons is a classical mechanism. As is the case throughout the central nervous system, fast synaptic excitation within and between brain regions relevant to epilepsy is mediated predominantly by AMPA receptors. By inhibiting glutamate-mediated excitation, AMPA receptor antagonists markedly reduce or abolis...
Source: Acta Neurologica Scandinavica. Supplementum - May 25, 2013 Category: Neurology Authors: Rogawski MA Tags: Acta Neurol Scand Suppl Source Type: research

Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist.
Abstract Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile; E2007] is a potent, selective, orally active non-competitive AMPA receptor antagonist developed for the treatment of epilepsy. Perampanel has a 2,3'-bipyridin-6'-one core structure, distinguishing it chemically from other AMPA receptor antagonist classes. Studies in various physiological systems indicate that perampanel selectively inhibits AMPA receptor-mediated synaptic excitation without affecting NMDA receptor responses. Blocking of AMPA receptors occurs at an allosteric site that is distinct from the glutamate ...
Source: Acta Neurologica Scandinavica. Supplementum - May 25, 2013 Category: Neurology Authors: Rogawski MA, Hanada T Tags: Acta Neurol Scand Suppl Source Type: research

Efficacy of perampanel: a review of clinical trial data.
Abstract The efficacy of adjunctive perampanel has been investigated in an extensive clinical development program across a broad, multinational population of patients with refractory partial-onset seizures. Further to the results of two Phase II dose-finding studies, perampanel was evaluated in three large Phase III registration studies at the predicted no-effect dose of 2 mg/day and the predicted effective doses of 4, 8, and 12 mg/day. In all three studies, perampanel 4, 8, and 12 mg/day consistently provided significant reductions in the frequency of partial-onset seizures compared with placebo. Improvem...
Source: Acta Neurologica Scandinavica. Supplementum - May 25, 2013 Category: Neurology Authors: Kerling F, Kasper BS Tags: Acta Neurol Scand Suppl Source Type: research

Safety and tolerability of perampanel: a review of clinical trial data.
Abstract The Phase II and Phase III clinical development program of perampanel is providing a wealth of data on the safety and tolerability of this alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist as an adjuvant treatment for refractory partial-onset seizures. In Phase II dose-finding studies, perampanel was associated with an acceptable tolerability profile up to the maximum evaluated dose of 12 mg/day. Subsequent multinational, multicenter, randomized, double-blind, placebo-controlled Phase III registration studies further supported the tolerability of perampanel across...
Source: Acta Neurologica Scandinavica. Supplementum - May 25, 2013 Category: Neurology Authors: Serratosa JM, Villanueva V, Kerling F, Kasper BS Tags: Acta Neurol Scand Suppl Source Type: research

Perampanel: expanding therapeutic options for patients with medically refractory secondary generalized convulsive seizures.
Abstract To evaluate the efficacy of adjunctive, once-daily perampanel against secondarily generalized (SG) seizures in three Phase III trials (studies 304, 305, and 306) and their extension (study 307). The Phase III studies enrolled patients (≥ 12 years) with uncontrolled partial-onset seizures despite treatment with 1-3 concomitant antiepileptic drugs. Patients completing the core Phase III studies were eligible for the extension study. Endpoints included median percent change in SG seizure frequency, 50% responder (proportion of patients achieving a ≥ 50% reduction in SG seizure frequency), 75% res...
Source: Acta Neurologica Scandinavica. Supplementum - May 25, 2013 Category: Neurology Authors: Ko D, Ramsay RE Tags: Acta Neurol Scand Suppl Source Type: research

The Norwegian Brain Council ('Hjernerådet') - united efforts are necessary!
Abstract There is a strong tradition of neuroscience in Norway, and Norwegian neurologists have been actively involved in developing partnerships between all those who recognize the importance of the brain and of brain diseases. It was therefore unsurprising that Norwegian neurologists took the initiative in establishing the Norwegian Brain Council (NBC). NBC was founded in 2007 and now comprises 27 organizations and institutions. It includes all those who work with brain research and brain diseases in Norway, as well as all relevant user organizations. Industries and businesses that are related to brain d...
Source: Acta Neurologica Scandinavica. Supplementum - January 11, 2013 Category: Neurology Authors: Gjerstad L, Gilhus NE, Stovner LJ, Hoff JM Tags: Acta Neurol Scand Suppl Source Type: research

Common imitators of epilepsy.
Abstract Many episodic phenomena involving motor, sensory, autonomic, and behavioral functions may imitate epilepsy. The aim of this article is to focus on the various manifestations and the diagnostic and therapeutic challenges of the most common of these disorders, as well as their relationship to emotional aspects. Syncope is caused by reduced global cerebral perfusion. Convulsive movements are sometimes released from subcortical structures, but do not follow the characteristic sequence of tonic-clonic seizures, and postictal symptoms are minimal. Hyperventilation attacks are caused by the metabolic con...
Source: Acta Neurologica Scandinavica. Supplementum - January 11, 2013 Category: Neurology Authors: Brodtkorb E Tags: Acta Neurol Scand Suppl Source Type: research